Yasaman Iranmanesh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Yasaman Iranmanesh has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Catherine Handy Marshall
Sidney Kimmel Comprehensive Cancer Center 1 Baltimore, Maryland
2 shared publications - Emmanuel S. Antonarakis
Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA
2 shared publications - Mark Christopher Markowski
Sidney Kimmel Comprehensive Cancer Center 1 Baltimore, Maryland
2 shared publications - Michael Anthony Carducci
Johns Hopkins School of Medicine Department of Oncology Baltimore, Maryland, 21287
2 shared publications - Samuel R. Denmeade
Sidney Kimmel Comprehensive Cancer Center 1 Baltimore, Maryland
2 shared publications - Adel Mandl
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, MD
1 shared publication
Latest Publications
- Open Access
- 23 September 2026
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 31 (11)
Long-term outcomes and treatment cessation in patients with response to first-line treatment of metastatic prostate cancer
Background and objective: Approximately one-third of men with metastatic prostate cancer die from causes other than prostate cancer. Little is known about the long-term outcomes of men with metastatic prostate cancer, in particular those who do not develop androgen pathway resistance. The objective of this study is to describe those with long-term survival and disease response to initial therapy and their clinical outcomes. Methods: This is a single-institution, retrospective study of patients with metastatic hormone-sensitive prostate cancer diagnosed prior to January 1, 2019 and alive as of December 31, 2024. Clinical and demographic features are described at baseline and follow-up, with outcomes after treatment cessation. Key findings and limitations: One hundred and forty-five patients were included with a median age at diagnosis of 61 years. Fifty-one patients (35.2%) had metastatic disease at diagnosis, and 108 (74.5%) had bone metastases at the time of metastatic disease. The median follow-up from the date of metastatic disease was 8.4 years. Eighty-nine (61.4%) patients continued to have disease response to initial therapy after a median of 8.8 years. Thirty-two patients stopped therapy, and of those, 25 recovered testosterone, with 11 patients continuing to have an undetectable prostate-specific antigen (8% of total cohort and 34% of those who stopped therapy). Conclusions and clinical implications: In this cohort, most patients did not have further progression of disease, and 8% of patients had durable treatment-free remissions. Further research is needed on treatment cessation in men with exceptional responses to androgen deprivation therapy.
- 23 September 2026
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 31 (11)
Open AccessLong-term outcomes and treatment cessation in patients with response to first-line treatment of metastatic prostate cancer
Background and objective: Approximately one-third of men with metastatic prostate cancer die from causes other than prostate cancer. Little is known about the long-term outcomes of men with metastatic prostate cancer, in particular those who do not develop androgen pathway resistance. The objective of this study is to describe those with long-term survival and disease response to initial therapy and their clinical outcomes. Methods: This is a single-institution, retrospective study of patients with metastatic hormone-sensitive prostate cancer diagnosed prior to January 1, 2019 and alive as of December 31, 2024. Clinical and demographic features are described at baseline and follow-up, with outcomes after treatment cessation. Key findings and limitations: One hundred and forty-five patients were included with a median age at diagnosis of 61 years. Fifty-one patients (35.2%) had metastatic disease at diagnosis, and 108 (74.5%) had bone metastases at the time of metastatic disease. The median follow-up from the date of metastatic disease was 8.4 years. Eighty-nine (61.4%) patients continued to have disease response to initial therapy after a median of 8.8 years. Thirty-two patients stopped therapy, and of those, 25 recovered testosterone, with 11 patients continuing to have an undetectable prostate-specific antigen (8% of total cohort and 34% of those who stopped therapy). Conclusions and clinical implications: In this cohort, most patients did not have further progression of disease, and 8% of patients had durable treatment-free remissions. Further research is needed on treatment cessation in men with exceptional responses to androgen deprivation therapy.
- 19 February 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- p. OP2500688
Comparison of Characteristics and Outcomes of Patients With Metastatic Prostate Cancer With and Without Next-Generation Sequencing Testing
PURPOSE: Next-generation sequencing (NGS) is recommended for patients with metastatic prostate cancer (PC). Nationwide, testing rates are low. Whether PC disease characteristics and courses differ between those with and without NGS testing is unknown. We identified predictors of testing, explored likely reasons for lack of testing, and compared survival between those with and without testing. METHODS: We retrospectively reviewed patients with metastatic PC initially seen between 2020 and 2022 at Johns Hopkins. Clinical data and reasons for nontesting were abstracted from the electronic medical record. We conducted a logistic regression assessing predictors of NGS testing, adjusting for age, Gleason grade, marital status, and metastatic diagnosis year. We used Cox regression to compare overall survival, defined from the time patients had both a metastatic diagnosis and a visit at our institution until death/last follow-up, between those tested and not tested. We adjusted for age, Gleason grade, initial metastasis (M) stage, comorbidities, and time from metastatic diagnosis to first visit. RESULTS: Of the 435 patients, 257 (59%) had NGS testing. Older patients were less likely to have testing (adjusted odds ratio [aOR], 0.96 [95% CI, 0.94 to 0.98]). Unmarried patients were less likely to have testing (aOR, 0.62 [95% CI, 0.38 to 1.01]). Patients with Gleason Grade Group 5 were more likely to undergo testing than patients with Groups 1-3 (aOR, 1.86 [95% CI, 1.14 to 3.04]). Among those without testing, 139 (78%) had at least one potential reason for lack of testing in the medical record. The most common reason for nontesting was patient/disease factors (37%). CONCLUSION: Older and unmarried men with metastatic PC were less likely to obtain NGS testing, whereas those with high Gleason grade were more likely. Interventions are needed to improve testing rates.
- 19 February 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- p. OP2500688
Comparison of Characteristics and Outcomes of Patients With Metastatic Prostate Cancer With and Without Next-Generation Sequencing Testing
PURPOSE: Next-generation sequencing (NGS) is recommended for patients with metastatic prostate cancer (PC). Nationwide, testing rates are low. Whether PC disease characteristics and courses differ between those with and without NGS testing is unknown. We identified predictors of testing, explored likely reasons for lack of testing, and compared survival between those with and without testing. METHODS: We retrospectively reviewed patients with metastatic PC initially seen between 2020 and 2022 at Johns Hopkins. Clinical data and reasons for nontesting were abstracted from the electronic medical record. We conducted a logistic regression assessing predictors of NGS testing, adjusting for age, Gleason grade, marital status, and metastatic diagnosis year. We used Cox regression to compare overall survival, defined from the time patients had both a metastatic diagnosis and a visit at our institution until death/last follow-up, between those tested and not tested. We adjusted for age, Gleason grade, initial metastasis (M) stage, comorbidities, and time from metastatic diagnosis to first visit. RESULTS: Of the 435 patients, 257 (59%) had NGS testing. Older patients were less likely to have testing (adjusted odds ratio [aOR], 0.96 [95% CI, 0.94 to 0.98]). Unmarried patients were less likely to have testing (aOR, 0.62 [95% CI, 0.38 to 1.01]). Patients with Gleason Grade Group 5 were more likely to undergo testing than patients with Groups 1-3 (aOR, 1.86 [95% CI, 1.14 to 3.04]). Among those without testing, 139 (78%) had at least one potential reason for lack of testing in the medical record. The most common reason for nontesting was patient/disease factors (37%). CONCLUSION: Older and unmarried men with metastatic PC were less likely to obtain NGS testing, whereas those with high Gleason grade were more likely. Interventions are needed to improve testing rates.